{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:18:07Z","timestamp":1785752287867,"version":"3.56.0"},"reference-count":57,"publisher":"American Veterinary Medical Association (AVMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"Abstract<\/jats:title>\n\nOBJECTIVE<\/jats:title>\nTo evaluate survival times for dogs with previously untreated, peripheral nodal, intermediate- or large-cell lymphoma treated with prednisone alone.<\/jats:p>\n<\/jats:sec>\n\nANIMALS<\/jats:title>\n109 client-owned dogs recruited from 15 institutions in the United States.<\/jats:p>\n<\/jats:sec>\n\nPROCEDURES<\/jats:title>\nDogs were treated with prednisone at a dosage of 40 mg\/m2<\/jats:sup>, PO, once daily for 7 days and at a dosage of 20 mg\/m2<\/jats:sup>, PO, once daily thereafter. Quality of life (QOL) was assessed by owners with a visual analog scale when treatment was started (day 0), 1 and 2 weeks after treatment was started, and every 4 weeks thereafter. The primary outcome of interest was survival time as determined by the Kaplan-Meier method. Factors potentially associated with survival time were examined.<\/jats:p>\n<\/jats:sec>\n\nRESULTS<\/jats:title>\nMedian overall survival time was 50 days (95% CI, 41 to 59 days). Factors associated with survival time included substage (a vs b) and immunopheno-type (B cell vs T cell). Owner-assigned QOL scores on days 0 and 14 were significantly positively correlated with survival time. When QOL score was dichotomized, dogs with day 0 or day 14 QOL scores \u2265 50 had significantly longer survival times, compared with dogs with day 0 or day 14 QOL scores < 50. No variables were predictive of long-term (> 120 days) survival.<\/jats:p>\n<\/jats:sec>\n\nCONCLUSIONS AND CLINICAL RELEVANCE<\/jats:title>\nResults suggested that survival times were short for dogs with previously untreated, peripheral nodal, intermediate- or large-cell lymphoma treated with prednisone alone. Owner-perceived QOL and clinician-assigned sub-stage were both associated with survival time. Findings provide potentially important information for clinicians to discuss with owners of dogs with lymphoma at the time treatment decisions are made. (J Am Vet Med Assoc<\/jats:italic> 2021;259:62\u201371)<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.259.1.62","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T18:08:12Z","timestamp":1623694092000},"page":"62-71","source":"Crossref","is-referenced-by-count":14,"title":["Survival time for dogs with previously untreated, peripheral nodal, intermediate- or large-cell lymphoma treated with prednisone alone: the Canine Lymphoma Steroid Only trial"],"prefix":"10.2460","volume":"259","author":[{"given":"Kenneth M.","family":"Rassnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis B.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra A.","family":"Kamstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey J.","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika P.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B.","family":"Flory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Kiselow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne L.","family":"Intile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Malone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Musser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Yanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad M.","family":"Johannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"R1","series-title":"Vet Pathol","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1177\/0300985813478210","article-title":"Canine lymphomas: association of classification type, disease stage, tumor sub-type, mitotic rate, and treatment with survival","volume":"50","author":"Valli VE","year":"2013","unstructured":"Valli VE, Kass PH, San Myint M, Canine lymphomas: association of classification type, disease stage, tumor sub-type, mitotic rate, and treatment with survival. Vet Pathol 2013;50:738\u2013748.10.1177\/0300985813478210"},{"issue":"suppl 1","key":"R2","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/vco.12155","article-title":"Canine small clear cell\/T-zone lymphoma: clinical presentation and outcome in a retrospective case series","volume":"14","author":"Martini V","year":"2016","unstructured":"Martini V, Marconato L, Poggi A, Canine small clear cell\/T-zone lymphoma: clinical presentation and outcome in a retrospective case series. Vet Comp Oncol 2016;14(suppl 1):117\u2013126.10.1111\/vco.12155"},{"key":"R3","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1476-5829.2011.00317.x","article-title":"Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma","volume":"11","author":"Flood-Knapik KE","year":"2013","unstructured":"Flood-Knapik KE, Durham AC, Gregor TP, Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. Vet Comp Oncol 2013;11:272\u2013286.10.1111\/j.1476-5829.2011.00317.x"},{"key":"R4","series-title":"J Am Vet Med Assoc","first-page":"47","article-title":"Chemotherapy of malignant lymphoma in dogs and cats","volume":"153","author":"Brick JO","year":"1968","unstructured":"Brick JO, Roenigk WJ, Wilson GP. Chemotherapy of malignant lymphoma in dogs and cats. J Am Vet Med Assoc 1968;153:47\u201352."},{"key":"R5","series-title":"Top Companion Anim Med","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.tcam.2009.03.003","article-title":"Lymphoma: which chemotherapy protocol and why?","volume":"24","author":"Chun R.","year":"2009","unstructured":"Chun R. Lymphoma: which chemotherapy protocol and why? Top Companion Anim Med 2009;24:157\u2013162.10.1053\/j.tcam.2009.03.003"},{"key":"R6","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1476-5829.2012.00318.x","article-title":"Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians","volume":"11","author":"Regan RC","year":"2013","unstructured":"Regan RC, Kaplan MS, Bailey DB. Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians. Vet Comp Oncol 2013;11:287\u2013295.10.1111\/j.1476-5829.2012.00318.x"},{"key":"R7","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1939-1676.2006.tb02868.x","article-title":"A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma","volume":"20","author":"Frimberger AE","year":"2006","unstructured":"Frimberger AE, Moore AS, Rassnick KM, A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Intern Med 2006;20:355\u2013364.10.1111\/j.1939-1676.2006.tb02868.x"},{"key":"R8","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1939-1676.2012.00980.x","article-title":"Autologous peripheral blood hematopoietic cell transplantation in dogs with B-cell lymphoma","volume":"26","author":"Willcox JL","year":"2012","unstructured":"Willcox JL, Pruitt A, Suter SE. Autologous peripheral blood hematopoietic cell transplantation in dogs with B-cell lymphoma. J Vet Intern Med 2012;26:1155\u20131163.10.1111\/j.1939-1676.2012.00980.x"},{"key":"R9","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/jvim.12302","article-title":"Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma","volume":"28","author":"Warry EE","year":"2014","unstructured":"Warry EE, Willcox JL, Suter SE. Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma. J Vet Intern Med 2014;28:529\u2013537.10.1111\/jvim.12302"},{"key":"R10","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1939-1676.2000.tb02224.x","article-title":"Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"14","author":"Chun R","year":"2000","unstructured":"Chun R, Garrett LD, Vail DM. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2000;14:120\u2013124.10.1111\/j.1939-1676.2000.tb02224.x"},{"key":"R11","series-title":"Vet Comp Oncol","first-page":"196","article-title":"Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases","volume":"8","author":"Sorenmo K","year":"2010","unstructured":"Sorenmo K, Overley B, Krick E, Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases. Vet Comp Oncol 2010;8:196\u2013208."},{"key":"R12","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1476-5829.2012.00324.x","article-title":"Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma","volume":"11","author":"Burton JH","year":"2013","unstructured":"Burton JH, Garrett-Mayer E, Thamm DH. Evaluation of a 15-week CHOP protocol for the treatment of canine multicentric lymphoma. Vet Comp Oncol 2013;11:306\u2013315.10.1111\/j.1476-5829.2012.00324.x"},{"key":"R13","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1111\/j.1939-1676.2007.tb01960.x","article-title":"Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma","volume":"21","author":"Rassnick KM","year":"2007","unstructured":"Rassnick KM, McEntee MC, Erb HN, Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma. J Vet Intern Med 2007;21:1364\u20131373.10.1111\/j.1939-1676.2007.tb01960.x"},{"key":"R14","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1939-1676.2004.tb02609.x","article-title":"Chemotherapy followed by half-body radiation therapy for canine lymphoma","volume":"18","author":"Williams LE","year":"2004","unstructured":"Williams LE, Johnson JL, Hauck ML, Chemotherapy followed by half-body radiation therapy for canine lymphoma. J Vet Intern Med 2004;18:703\u2013709.10.1111\/j.1939-1676.2004.tb02609.x"},{"key":"R15","series-title":"Vet J","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.tvjl.2015.10.008","article-title":"Cancer immunotherapy in veterinary medicine: current options and new developments","volume":"207","author":"Regan D","year":"2016","unstructured":"Regan D, Guth A, Coy J, Cancer immunotherapy in veterinary medicine: current options and new developments. Vet J 2016;207:20\u201328.10.1016\/j.tvjl.2015.10.008"},{"key":"R16","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/jvim.14700","article-title":"Alternating rabacfosa-dine\/doxorubicin: efficacy and tolerability in naive canine multicentric lymphoma","volume":"31","author":"Thamm DH","year":"2017","unstructured":"Thamm DH, Vail DM, Post GS, Alternating rabacfosa-dine\/doxorubicin: efficacy and tolerability in naive canine multicentric lymphoma. J Vet Intern Med 2017;31:872\u2013878.10.1111\/jvim.14700"},{"key":"R17","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/j.1939-1676.2002.tb02411.x","article-title":"Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma","volume":"16","author":"Garrett LD","year":"2002","unstructured":"Garrett LD, Thamm DH, Chun R, Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704\u2013 709.10.1111\/j.1939-1676.2002.tb02411.x"},{"key":"R18","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2460\/javma.238.4.480","article-title":"Predictors of long-term survival in dogs with high-grade multicentric lymphoma","volume":"238","author":"Marconato L","year":"2011","unstructured":"Marconato L, Stefanello D, Valenti P, Predictors of long-term survival in dogs with high-grade multicentric lymphoma. J Am Vet Med Assoc 2011;238:480\u2013485.10.2460\/javma.238.4.480"},{"key":"R19","series-title":"Vet Rec","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/vr.152.3.77","article-title":"Study of dog and cat owners\u2019 perceptions of medical treatment for cancer","volume":"152","author":"nden LB","year":"2003","unstructured":"Br\u00f8nden LB, Rutteman GR, Flagstad A, Study of dog and cat owners\u2019 perceptions of medical treatment for cancer. Vet Rec 2003;152:77\u201380.10.1136\/vr.152.3.77"},{"key":"R20","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1748-5827.2003.tb00127.x","article-title":"Owners\u2019 assessments of their dog's quality of life during palliative chemotherapy for lymphoma","volume":"44","author":"Mellanby RJ","year":"2003","unstructured":"Mellanby RJ, Herrtage ME, Dobson JM. Owners\u2019 assessments of their dog's quality of life during palliative chemotherapy for lymphoma. J Small Anim Pract 2003;44:100\u2013103.10.1111\/j.1748-5827.2003.tb00127.x"},{"key":"R21","series-title":"J Am Vet Med Assoc","first-page":"1348","article-title":"Pet health insurance helping more pet owners afford optimal care","volume":"244","author":"Burns K.","year":"2014","unstructured":"Burns K. Pet health insurance helping more pet owners afford optimal care. J Am Vet Med Assoc 2014;244:1348\u20131353."},{"key":"R22","series-title":"Animals (Basel)","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ani7030018","article-title":"Factors which influence owners when deciding to use chemotherapy in terminally ill pets","volume":"7","author":"Williams J","year":"2017","unstructured":"Williams J, Phillips C, Byrd HM. Factors which influence owners when deciding to use chemotherapy in terminally ill pets. Animals (Basel) 2017;7:18.10.3390\/ani7030018"},{"key":"R23","series-title":"Cell Death Differ","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.cdd.4400969","article-title":"Recent insights into the mechanism of glucocorticosteroid-induced apoptosis","volume":"9","author":"Distelhorst CW","year":"2002","unstructured":"Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid-induced apoptosis. Cell Death Differ 2002;9:6\u201319.10.1038\/sj.cdd.4400969"},{"key":"R24","series-title":"Clin Cancer Res","first-page":"1681","article-title":"Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies","volume":"8","author":"Greenstein S","year":"2002","unstructured":"Greenstein S, Ghias K, Krett NL, Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002;8:1681\u20131694."},{"key":"R25","series-title":"Res Vet Sci","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.rvsc.2010.03.017","article-title":"A novel NF-kappaB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors","volume":"89","author":"Matsuda A","year":"2010","unstructured":"Matsuda A, Tanaka A, Muto S, A novel NF-kappaB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Res Vet Sci 2010;89:378\u2013382.10.1016\/j.rvsc.2010.03.017"},{"key":"R26","series-title":"J Natl Cancer Inst","first-page":"565","article-title":"Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy","volume":"51","author":"Squire RA","year":"1973","unstructured":"Squire RA, Bush M, Melby EC, Clinical and pathologic study of canine lymphoma: clinical staging, cell classification, and therapy. J Natl Cancer Inst 1973;51:565\u2013574."},{"key":"R27","series-title":"Blood","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1182\/blood.V63.2.380.380","article-title":"Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single-agent glucocorticoid treatment","volume":"63","author":"Bell R","year":"1984","unstructured":"Bell R, Cotter S, Lillquist A, Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single-agent glucocorticoid treatment. Blood 1984;63:380\u2013383.10.1182\/blood.V63.2.380.380"},{"key":"R28","first-page":"91","article-title":"Hemolymphatic system","author":"Raskin RE","year":"2016","unstructured":"Raskin RE. Hemolymphatic system. In: Raskin RE, Meyer DJ, eds. Canine and feline cytology. 3rd ed. St Louis: Elsevier, 2016;91\u2013137."},{"key":"R29","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1476-5829.2010.00244.x","article-title":"Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer","volume":"9","author":"Lynch S","year":"2011","unstructured":"Lynch S, Savary-Bataille K, Leeuw B, Development of a questionnaire assessing health-related quality-of-life in dogs and cats with cancer. Vet Comp Oncol 2011;9:172\u2013182.10.1111\/j.1476-5829.2010.00244.x"},{"key":"R30","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"852","DOI":"10.2460\/javma.252.7.852","article-title":"Usefulness of chemotherapy for the treatment of very elderly dogs with multicentric lymphoma","volume":"252","author":"Moore AS","year":"2018","unstructured":"Moore AS, Frimberger AE. Usefulness of chemotherapy for the treatment of very elderly dogs with multicentric lymphoma. J Am Vet Med Assoc 2018;252:852\u2013859.10.2460\/javma.252.7.852"},{"key":"R31","series-title":"Vet Clin North Am","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0091-0279(77)50009-3","article-title":"Diagnosis and treatment of canine hematopoietic neoplasms","volume":"7","author":"MacEwen EG","year":"1977","unstructured":"MacEwen EG, Patnaik AK, Wilkins RJ. Diagnosis and treatment of canine hematopoietic neoplasms. Vet Clin North Am 1977;7:105\u2013118.10.1016\/S0091-0279(77)50009-3"},{"key":"R32","first-page":"688","article-title":"Canine lymphoma and lymphocytic leukemias","author":"Vail DM","year":"2019","unstructured":"Vail DM, Pinkerton M, Young KM. Canine lymphoma and lymphocytic leukemias. In: Vail DM, Thamm D, Liptak J, eds. Withrow and MacEwen's small animal clinical oncology. 6th ed. St Louis: Elsevier, 2019;688\u2013714."},{"key":"R33","first-page":"2065","article-title":"Hematopoietic tumors","author":"Vail DM","year":"2017","unstructured":"Vail DM. Hematopoietic tumors. In: Ettinger SJ, Feldman EC, Cote E, eds. Textbook of veterinary internal medicine expert consult. 8th ed. St Louis: Elsevier, 2017;2065\u20132077."},{"key":"R34","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1939-1676.2008.0270.x","article-title":"Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs","volume":"23","author":"Rassnick KM","year":"2009","unstructured":"Rassnick KM, Moore AS, Collister KE, Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs. J Vet Intern Med 2009;23:317\u2013322.10.1111\/j.1939-1676.2008.0270.x"},{"key":"R35","series-title":"Vet Pathol","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1177\/0300985810363902","article-title":"A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology","volume":"47","author":"Ponce F","year":"2010","unstructured":"Ponce F, Marchal T, Magnol JP, A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol 2010;47:414\u2013433.10.1177\/0300985810363902"},{"key":"R36","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/vco.12320","article-title":"Prognostic significance of morphotypes in canine lymphomas: a systematic review of literature","volume":"16","author":"Sayag D","year":"2018","unstructured":"Sayag D, Fournel-Fleury C, Ponce F. Prognostic significance of morphotypes in canine lymphomas: a systematic review of literature. Vet Comp Oncol 2018;16:12\u201319.10.1111\/vco.12320"},{"key":"R37","series-title":"Front Vet Sci","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fvets.2016.00077","article-title":"Canine lymphoma, more than a morphological diagnosis: what we have learned about diffuse large B-cell lymphoma","volume":"3","author":"Aresu L.","year":"2016","unstructured":"Aresu L. Canine lymphoma, more than a morphological diagnosis: what we have learned about diffuse large B-cell lymphoma. Front Vet Sci 2016;3:77.10.3389\/fvets.2016.00077"},{"key":"R38","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail DM","year":"2010","unstructured":"Vail DM, Michels GM, Khanna C, Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol 2010;8:28\u201337.10.1111\/j.1476-5829.2009.00200.x"},{"key":"R39","series-title":"Vet J","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.tvjl.2013.03.021","article-title":"Development and validation of a survey for quality of life assessment by owners of healthy dogs","volume":"197","author":"Lavan RP","year":"2013","unstructured":"Lavan RP. Development and validation of a survey for quality of life assessment by owners of healthy dogs. Vet J 2013;197:578\u2013582.10.1016\/j.tvjl.2013.03.021"},{"key":"R40","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.2460\/javma.252.9.1073","article-title":"Development and psychometric testing of the Canine Owner-Reported Quality of Life questionnaire, an instrument designed to measure quality of life in dogs with cancer","volume":"252","author":"Giuffrida MA","year":"2018","unstructured":"Giuffrida MA, Cimino Brown D, Ellenberg SS, Development and psychometric testing of the Canine Owner-Reported Quality of Life questionnaire, an instrument designed to measure quality of life in dogs with cancer. J Am Vet Med Assoc 2018;252:1073\u20131083.10.2460\/javma.252.9.1073"},{"key":"R41","series-title":"Vet Ophthalmol","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/vop.12623","article-title":"Bilateral enucleation in dogs: a review of owner perceptions and satisfaction","volume":"22","author":"Hamzianpour N","year":"2019","unstructured":"Hamzianpour N, Smith K, Dawson C, Bilateral enucleation in dogs: a review of owner perceptions and satisfaction. Vet Ophthalmol 2019;22:566\u2013576.10.1111\/vop.12623"},{"key":"R42","series-title":"Vet Ophthalmol","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1463-5224.2011.00972.x","article-title":"Parotid duct transposition in dogs: a retrospective review of 92 eyes from 1999 to 2009","volume":"15","author":"Rhodes M","year":"2012","unstructured":"Rhodes M, Heinrich C, Featherstone H, Parotid duct transposition in dogs: a retrospective review of 92 eyes from 1999 to 2009. Vet Ophthalmol 2012;15:213\u2013222.10.1111\/j.1463-5224.2011.00972.x"},{"key":"R43","series-title":"Vet Rec","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/vr.147.12.325","article-title":"Long-term outcome of surgery for dogs with cranial cruciate ligament deficiency","volume":"147","author":"Innes JF","year":"2000","unstructured":"Innes JF, Bacon D, Lynch C, Long-term outcome of surgery for dogs with cranial cruciate ligament deficiency. Vet Rec 2000;147:325\u2013328.10.1136\/vr.147.12.325"},{"key":"R44","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/vco.12393","article-title":"Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide","volume":"16","author":"Polton G","year":"2018","unstructured":"Polton G, Finotello R, Sabattini S, Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide. Vet Comp Oncol 2018;16:399\u2013408.10.1111\/vco.12393"},{"key":"R45","series-title":"Vet Med Sci","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/vms3.232","article-title":"Health-related quality of life in dogs treated with electrochemotherapy and\/or inter-leukin-12 gene electrotransfer","volume":"6","author":"Milevoj N","year":"2020","unstructured":"Milevoj N, Tozon N, Licen S, Health-related quality of life in dogs treated with electrochemotherapy and\/or inter-leukin-12 gene electrotransfer. Vet Med Sci 2020;6:290\u2013298.10.1002\/vms3.232"},{"key":"R46","series-title":"Hematol Oncol","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1002\/hon.2522","article-title":"Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma","volume":"36","author":"Thompson CA","year":"2018","unstructured":"Thompson CA, Yost KJ, Maurer MJ, Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 2018;36:749\u2013756.10.1002\/hon.2522"},{"issue":"suppl 1","key":"R47","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/vco.12086","article-title":"Criteria for designation of clinical substage in canine lymphoma: a survey of veterinary oncologists","volume":"14","author":"Barber LG","year":"2016","unstructured":"Barber LG, Weishaar KM. Criteria for designation of clinical substage in canine lymphoma: a survey of veterinary oncologists. Vet Comp Oncol 2016;14(suppl 1):32\u201339.10.1111\/vco.12086"},{"key":"R48","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1939-1676.2009.0289.x","article-title":"Asparaginase and MOPP treatment of dogs with lymphoma","volume":"23","author":"Brodsky EM","year":"2009","unstructured":"Brodsky EM, Maudlin GN, Lachowicz JL, Asparaginase and MOPP treatment of dogs with lymphoma. J Vet Intern Med 2009;23:578\u2013584.10.1111\/j.1939-1676.2009.0289.x"},{"key":"R49","series-title":"Vet Comp Oncol","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1476-5829.2010.00230.x","article-title":"CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma","volume":"9","author":"Rebhun RB","year":"2011","unstructured":"Rebhun RB, Kent MS, Borrofka SA, CHOP chemotherapy for the treatment of canine multicentric T-cell lymphoma. Vet Comp Oncol 2011;9:38\u201344.10.1111\/j.1476-5829.2010.00230.x"},{"key":"R50","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1939-1676.1991.tb00939.x","article-title":"The influence of corticosteroids on host defense mechanisms","volume":"5","author":"Cohn LA","year":"1991","unstructured":"Cohn LA. The influence of corticosteroids on host defense mechanisms. J Vet Intern Med 1991;5:95\u2013104.10.1111\/j.1939-1676.1991.tb00939.x"},{"key":"R51","series-title":"In Vivo","first-page":"843","article-title":"The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines","volume":"28","author":"Pawlak A","year":"2014","unstructured":"Pawlak A, Rapak A, Zbyryt I, The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines. In Vivo 2014;28:843\u2013850."},{"key":"R52","series-title":"J Vet Pharmacol Ther","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/jvp.12837","article-title":"Development of prednisone resistance in naive canine lymphoma: longitudinal evaluation of NR3C1alpha, ABCB1, and 11beta-HSD mRNA expression","volume":"43","author":"Hanot CC","year":"2020","unstructured":"Hanot CC, Mealey KL, Fidel JL, Development of prednisone resistance in naive canine lymphoma: longitudinal evaluation of NR3C1alpha, ABCB1, and 11beta-HSD mRNA expression. J Vet Pharmacol Ther 2020;43:231\u2013236.10.1111\/jvp.12837"},{"key":"R53","series-title":"Oncologist","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1634\/theoncologist.5-3-238","article-title":"The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard?","volume":"5","author":"Moreno A","year":"2000","unstructured":"Moreno A, Colon-Otero G, Solberg LA Jr. The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin's lymphomas (NHL): is there a standard? Oncologist 2000;5:238\u2013249.10.1634\/theoncologist.5-3-238"},{"key":"R54","series-title":"J Vet Intern Med","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1939-1676.1991.tb03131.x","article-title":"Efficacy and toxicity of doxorubicin\/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma","volume":"5","author":"Price GS","year":"1991","unstructured":"Price GS, Page RL, Fischer BM, Efficacy and toxicity of doxorubicin\/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991;5:259\u2013262.10.1111\/j.1939-1676.1991.tb03131.x"},{"key":"R55","series-title":"J Small Anim Pract","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1748-5827.1994.tb03574.x","article-title":"Canine multicentric lymphoma 2: comparison of response to two chemotherapeutic protocols","volume":"35","author":"Dobson JM","year":"1994","unstructured":"Dobson JM, Gorman NT. Canine multicentric lymphoma 2: comparison of response to two chemotherapeutic protocols. J Small Anim Pract 1994;35:9\u201315.10.1111\/j.1748-5827.1994.tb03574.x"},{"key":"R56","series-title":"Cell Growth Differ","first-page":"1321","article-title":"Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids","volume":"6","author":"Schuetz JD","year":"1995","unstructured":"Schuetz JD, Silverman JA, Thottassery JV, Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ 1995;6:1321\u20131332."},{"key":"R57","series-title":"J Biol Chem","doi-asserted-by":"publisher","first-page":"27127","DOI":"10.1016\/S0021-9258(19)74226-4","article-title":"Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression","volume":"268","author":"Altuvia S","year":"1993","unstructured":"Altuvia S, Stein WD, Goldenberg S, Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression. J Biol Chem 1993;268:27127\u201327132.10.1016\/S0021-9258(19)74226-4"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/259\/1\/javma.259.1.62.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/259\/1\/javma.259.1.62.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/259\/1\/javma.259.1.62.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T01:37:29Z","timestamp":1696556249000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/259\/1\/javma.259.1.62.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":57,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.2460\/javma.259.1.62","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,1]]}}}